Avalo Therapeutics, Inc.
AVTX
$18.79
$1.8210.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.63M | -20.77M | -13.15M | -35.34M | 23.04M |
| Total Depreciation and Amortization | 59.00K | 134.00K | 135.00K | 68.00K | 34.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.35M | 5.63M | 2.36M | 20.84M | -33.09M |
| Change in Net Operating Assets | -1.15M | 3.61M | 1.20M | -612.00K | -1.51M |
| Cash from Operations | -16.37M | -11.39M | -9.46M | -15.04M | -11.53M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.26M | -70.86M | -- | -- | -- |
| Cash from Investing | -13.26M | -70.86M | -- | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14.37M | 40.00K | -- | 69.44M | 0.00 |
| Repurchase of Common Stock | -1.00K | -509.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1.73M | 0.00 |
| Cash from Financing | 14.37M | -469.00K | -- | 67.71M | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.26M | -82.72M | -9.46M | 52.67M | -11.53M |